Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Transcription factor 21 and prognosis in a CAD population
Session:
Comunicações Orais (Sessão 17) - Ciência Básica e Saúde Digital
Speaker:
M. Raquel Santos
Congress:
CPC 2022
Topic:
O. Basic Science
Theme:
36. Basic Science
Subtheme:
36.2 Basic Science - Cardiac Biology and Physiology
Session Type:
Comunicações Orais
FP Number:
---
Authors:
m. Raquel Santos; Maria Isabel Mendonça; Margarida Temtem; Débora sá; Ana Célia Sousa; Sónia Freitas; Mariana Rodrigues; Eva Henriques; Sofia Borges; Graça Guerra; Ana Freitas; Ilídio Ornelas; António Drumond; Roberto Palma Dos Reis
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt">TCF21 is a member of the basic- helix-loop-helix (bHLH) transcriptor factor family, being critical for embryogenesis of the heart. It regulates epicardium-derived cells differentiation into smooth muscle (SMC) and fibroblast lineages.</span><span style="font-size:12.0pt"> The biological roles of TCF21 in epicardial fate determination and the progression of atherosclerosis remained a controversial issue.</span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt">Aim:</span></strong><span style="font-size:12.0pt"> Investigate the impact of the TCF21 rs12190287 gene variant on the prognosis of a coronary artery disease (CAD) cohort.</span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt">Methods:</span></strong><span style="font-size:12.0pt"> 1,713 CAD patients mean age 53.3</span><span style="font-size:12.0pt">±</span><span style="font-size:12.0pt">7.8; 78.7% male sex were surveyed in terms of MACE occurrence in an extended follow of 5.0 </span><span style="font-size:12.0pt">±</span><span style="font-size:12.0pt">4.3 (range 1 to 20 years). After considering all the genetic models, we used the dominant (GC+CC) as the best model. This model was compared with the wild type of GG with Kaplan Meier methodology to evaluate the survival probability.<span style="color:black"> A</span> Cox regression analysis with all the risk factors and genetic models was performed to assess the independent variables associated with the prognosis. </span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt">Results: </span></strong></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt">GG wild genotype presented 9.5% of the whole population, GC 43.2 % and the risk genotype CC 47.3%. After Kaplan Meier estimated GC+CC showed a worse survival throughout the follow-up period.</span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt">After multivariate Cox regression analysis, this dominant model remained in the equation as an independent risk factor to MACE occurrence with an HR of 1.41; p=0.033, together with multivessel disease, physical inactivity, chronic kidney disease (CKD) and diabetes.</span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt">Conclusion:</span></strong><span style="font-size:12.0pt"> TCF21 rs12190287 is a risk factor for prognosis in our population. The role of this gene may influence fundamental SMC processes in response to vascular stress, accelerating atherosclerosis progression and may represent a target for future therapies.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site